ReviewOxidative medicine and cellular longevity2021
Molecular Mechanism of Astragaloside IV in Improving Endothelial Dysfunction of Cardiovascular Diseases Mediated by Oxidative Stress.
Review in Oxidative medicine and cellular longevity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- The interventional effect of astragaloside IV on rodent models of myocardial fibrosis: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Astragaloside IV Exhibited Antidiabetic Effects by Improving Glucose Metabolism, Repairing Damaged Gut Barrier and Regulating Intestinal Microbiota.Phytotherapy research : PTR · 2026Article
- Bioactive Constituents, Mechanisms, and Complementary Therapeutic Applications of Food-Medicine Continuum Materia Medica for Atherosclerosis Prevention and Treatment.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Astragaloside IV: A multipotent phytochemical for treating fibrotic diseases (Review).International journal of molecular medicine · 2026Review
- Multicellular Model Reveals the Mechanism of AEE Alleviating Vascular Endothelial Cell Injury via Anti-Inflammatory and Antioxidant Effects.International journal of molecular sciences · 2026Article
- Research Progress on Chemical Components ofMolecules (Basel, Switzerland) · 2025Review
- Astragaloside IV attenuates glucocorticoid-induced osteoclastogenesis and bone loss via the MAPK/NF-κB pathway.BMC complementary medicine and therapies · 2025Article
- Yiqi Huoxue Tongluo decoction combined with conventional medicine therapy: effects on restenosis rates and clinical efficacy in patients with coronary heart disease undergoing percutaneous coronary intervention.Frontiers in cardiovascular medicine · 2025Article
- Recent advances in the interaction of ferroptosis and immune-mediated inflammation in cardiovascular disease: mechanisms and therapeutic potential.Frontiers in immunology · 2025Review
- Astragaloside IV Reduces Lung Epithelial Cell Pyroptosis via TXNIP-NLRP3-GSDMD pathway.Cell biochemistry and biophysics · 2024Article
- Analysis of the predictive value of microRNA-199b-5p combined with nitric oxide for venous thrombosis in patients undergoing total knee arthroplasty.Journal of orthopaedic surgery and research · 2024Article
- The Antioxidant Action ofMolecules (Basel, Switzerland) · 2024Review
- A systematic review of astragaloside IV effects on animal models of diabetes mellitus and its complications.Heliyon · 2024Review
- Role of Natural Compounds Modulating Heme Catabolic Pathway in Gut, Liver, Cardiovascular, and Brain Diseases.Biomolecules · 2024Review
- Traditional Chinese medicine in thyroid-associated orbitopathy.Journal of endocrinological investigation · 2023Review
- Astragaloside IV Protects Detrusor from Partial Bladder Outlet Obstruction-Induced Oxidative Stress by Activating Mitophagy through AMPK-ULK1 Pathway.Oxidative medicine and cellular longevity · 2022Article
- Article
- Compounds purified from edible fungi fight against chronic inflammation through oxidative stress regulation.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endothelial dysfunction, induced by oxidative stress, is an essential factor affecting cardiovascular disease. Uncoupling of endothelial nitric oxide synthase (eNOS) leads to a decrease in nitric oxide (NO) production, an increase in reactive oxygen species (ROS) production, NO consumption, and NO synthesis. As a main active ingredient of astragalus, astragaloside IV can reduce the apoptosis of endothelial cells during oxidative stress. This review is aimed at exploring the mechanism of astragaloside IV in improving oxidative stress-mediated endothelial dysfunction relevant to cardiovascular diseases. The findings showed that the astragaloside IV can prevent or reverse the uncoupling of eNOS, increase eNOS and NO, and enhance several activating enzymes to activate the antioxidant system. In-depth validation and quantitative experiments still need to be implemented.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.